thalidomide has been researched along with Nerve Degeneration in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 5.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| "Sensory neuropathies developed in three of four patients with prurigo nodularis who had been treated with thalidomide." | 3.67 | Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. ( Antel, J; Aronson, IK; Van den Broek, H; West, DP; Yu, R, 1984) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 1.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| " The threshold neurotoxic dosage is lower than previously reported." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, JY | 2 |
| Huang, YN | 1 |
| Chiu, CC | 1 |
| Tweedie, D | 1 |
| Luo, W | 1 |
| Pick, CG | 1 |
| Chou, SY | 1 |
| Luo, Y | 1 |
| Hoffer, BJ | 1 |
| Greig, NH | 1 |
| Neymotin, A | 1 |
| Petri, S | 1 |
| Calingasan, NY | 1 |
| Wille, E | 1 |
| Schafer, P | 1 |
| Stewart, C | 1 |
| Hensley, K | 1 |
| Beal, MF | 1 |
| Kiaei, M | 1 |
| Zara, G | 1 |
| Ermani, M | 1 |
| Rondinone, R | 1 |
| Arienti, S | 1 |
| Doria, A | 1 |
| Aronson, IK | 1 |
| Yu, R | 1 |
| West, DP | 1 |
| Van den Broek, H | 1 |
| Antel, J | 1 |
| Vides, EA | 1 |
| Cabrera, A | 1 |
| Ahern, KP | 1 |
| Levis, WR | 1 |
| Schröder, JM | 2 |
| Gibbels, E | 2 |
| Matthiesen, T | 1 |
| Thomas, PK | 1 |
| Amelung, W | 1 |
| Püntmann, E | 1 |
| Fullerton, PM | 1 |
| O'Sullivan, DJ | 1 |
| McBride, WG | 1 |
| Scheid, W | 1 |
| Wieck, HH | 1 |
| Kinzel, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635] | Phase 3 | 159 participants (Actual) | Interventional | 2000-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Thalidomide | 117 |
| Placebo | 98 |
Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Thalidomide | 15 |
| Placebo | 9.6 |
1 review available for thalidomide and Nerve Degeneration
| Article | Year |
|---|---|
The morphological basis for alterations in nerve conduction in peripheral neuropathy.
Topics: Amyloidosis; Animals; Axons; Beriberi; Cresols; Demyelinating Diseases; Diabetic Neuropathies; Diffu | 1971 |
1 trial available for thalidomide and Nerve Degeneration
| Article | Year |
|---|---|
Effect of zafirlukast on leprosy reactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clofazimine; Cohort Studies; D | 1999 |
10 other studies available for thalidomide and Nerve Degeneration
| Article | Year |
|---|---|
Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.
Topics: Animals; Apoptosis; Brain Injuries, Traumatic; Cells, Cultured; Cerebral Cortex; Cytokines; Disease | 2016 |
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight | 2009 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures.
Topics: Adult; Aged; Animals; Cells, Cultured; Female; Fetus; Ganglia, Spinal; Humans; Male; Middle Aged; Ne | 1984 |
[Unmyelinated nerve fibers in senile nerves and in late thalidomide neuropathy: a quantitative electron microscopic study (author's transl)].
Topics: Aged; Aging; Axons; Biopsy; Female; Humans; Male; Microscopy, Electron; Middle Aged; Nerve Degenerat | 1977 |
Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity.
Topics: Animals; Female; Microscopy, Electron; Myelin Sheath; Nerve Degeneration; Neurons, Afferent; Periphe | 1985 |
[Clinical aspects and therapy of the so-called Contergan-polyneuropathy].
Topics: Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Nerve Degeneration; | 1966 |
Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study.
Topics: Action Potentials; Adult; Aged; Female; Follow-Up Studies; Humans; Leg; Median Nerve; Middle Aged; N | 1968 |
Fetal nerve cell degeneration produced by thalidomide in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Cell Nucleolus; Cell Nucleus; Dose-Response Relationship, Drug | 1974 |
[Thalidomide neuropathy in the late stage. A clinical documentation].
Topics: Aged; Female; Follow-Up Studies; Humans; Leprosy; Male; Middle Aged; Motor Neurons; Nerve Degenerati | 1973 |